RANKL signaling has been one of the important factors in the proliferation and multiplication of osteosarcoma [175] leading to the investigation of Denosumab a complete human monoclonal antibody against RANKL which has showed promising results for giant cell tumor of bone(GCTB). Here, TNFSF11 is linked to osteosarcoma.